You are here

  • Home
  • Archive
  • Volume 79, Issue Suppl 1
  • FRI0026 PROTEOMICS ANALYSIS COMPARING THE MODE OF ACTION OF UPADACITINIB AND ADALIMUMAB HEAD TO HEAD IN RA IDENTIFIES NOVEL, DISCRETE EARLY IMMUNE PATHWAY MODULATION IN THE SELECT-COMPARE PHASE 3 STUDY

Article info

Article menu
Download PDFPDF
Scientific Abstracts
Poster Presentations
Friday, 05 June 2020
Rheumatoid arthritis - prognosis, predictors and outcome
FRI0026 PROTEOMICS ANALYSIS COMPARING THE MODE OF ACTION OF UPADACITINIB AND ADALIMUMAB HEAD TO HEAD IN RA IDENTIFIES NOVEL, DISCRETE EARLY IMMUNE PATHWAY MODULATION IN THE SELECT-COMPARE PHASE 3 STUDY

Authors

Citation

Sornasse T, Song IH, Radstake T, et al
FRI0026 PROTEOMICS ANALYSIS COMPARING THE MODE OF ACTION OF UPADACITINIB AND ADALIMUMAB HEAD TO HEAD IN RA IDENTIFIES NOVEL, DISCRETE EARLY IMMUNE PATHWAY MODULATION IN THE SELECT-COMPARE PHASE 3 STUDY
Annals of the Rheumatic Diseases 2020;79:585-586.

Publication history

  • First published June 2, 2020.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.